

Regular Session, 2013

HOUSE BILL NO. 15

BY REPRESENTATIVES MACK, BROADWATER, TIM BURNS, COX, CROMER,  
HARRISON, HOWARD, IVEY, NANCY LANDRY, LORUSSO, MILLER,  
MORENO, PEARSON, POPE, REYNOLDS, SCHEXNAYDER, ST. GERMAIN,  
STOKES, AND WHITNEY

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) and to enact R.S.  
3 40:961(26.1), relative to controlled dangerous substances; to provide with respect to  
4 certain chemical groups within the cathinone Schedule I stimulants; to add  
5 substances to the listing of synthetic cannabinoids in Schedule I; to provide for  
6 definitions; to provide for certain exceptions; and to provide for related matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) are hereby amended and  
9 reenacted and R.S. 40:961(26.1) is hereby enacted to read as follows:

10 §961. Definitions

11 As used in this Part, the following terms shall have the meaning ascribed to  
12 them in this Section unless the context clearly indicates otherwise:

13 \* \* \*

14 (26.1) "Nitrogen-heterocyclic analog" means a nitrogen-heterocyclic analog  
15 of a synthetic cannabinoid which has a single carbon atom in a cyclic structure of a  
16 compound replaced by a nitrogen atom.

17 \* \* \*

18 §964. Composition of schedules

19 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.  
20 40:962, consist of the following drugs or other substances, by whatever official  
21 name, common or usual name, chemical name, or brand name designated:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

SCHEDULE I

\* \* \*

E. Stimulants. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Federal Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including its salts, isomers, esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible within the specific chemical designation:

\* \* \*

(9) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the following ways:

- (i) By substitution in the phenyl ring to any extent with alkyl, hydroxyl alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents.
- (ii) By substitution at the 3-position with an alkyl substituent.
- (iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, ~~or~~ benzyl ~~groups~~, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

F. Synthetic cannabinoids. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of a synthetic cannabinoid found to be in any of the following chemical groups, or any of those groups which contain any synthetic cannabinoid salts, isomers, ~~or~~ salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence of such salts, isomers, ~~or~~ salts of isomers, or nitrogen-heterocyclic analogs is possible within the specific chemical designation, ~~including all synthetic cannabinoid chemical analogues in such groups:~~

1 (1) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole  
 2 structure, whether or not substituted in the indole ring to any extent or the naphthyl  
 3 ring to any extent.

4 (2) Naphthylmethylindeles: any compound containing a 1-H-indol-3-yl-(1-  
 5 naphthyl)methane structure, whether or not substituted in the indole ring to any  
 6 extent or the naphthyl ring to any extent.

7 (3) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole  
 8 structure, whether or not substituted in the pyrrole ring to any extent or the naphthyl  
 9 ring to any extent.

10 (4) Naphthylmethylindenes: any compound containing a 1-(1-  
 11 naphthylmethyl)indene structure, whether or not substituted in the indene ring to any  
 12 extent or the naphthyl ring to any extent.

13 (5) Phenylacetylindoles: any compound containing a 3-phenylacetylindole  
 14 structure, whether or not substituted in the indole ring to any extent or the phenyl  
 15 ring to any extent.

16 (6) Cyclohexylphenols: any compound containing a 2-(3-  
 17 hydroxycyclohexyl)phenol structure, whether or not substituted in the cyclohexyl  
 18 ring to any extent or the phenyl ring to any extent.

19 ~~(7) Dibenzopyrans whether or not substituted in the cyclohexyl ring to any~~  
 20 ~~extent or the phenyl ring to any extent.~~

21 ~~(8)~~(7) Benzoylindoles: any compound containing a 3-(benzoyl)indole  
 22 structure, whether or not substituted in the indole ring to any extent or the phenyl  
 23 ring to any extent.

24 ~~(9)~~(8) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone  
 25 Tetrahydrodibenzopyrans whether or not substituted in the tricyclic ring system  
 26 except where contained in cannabis or cannabis resin.

27 ~~(10)~~(9) (1-(5-fluoropentyl)indol-3-yl)-  
 28 ~~(2,2,3,3-tetramethylcyclopropyl)methanone~~ Hexahydrodibenzopyrans whether or  
 29 not substituted in the tricyclic ring system except where contained in cannabis or  
 30 cannabis resin.

